4.48 0.1 (2.28%) | 07-26 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 5.31 | 1-year : | 6.2 |
Resists | First : | 4.55 | Second : | 5.31 |
Pivot price | 4.06 | |||
Supports | First : | 3.5 | Second : | 2.85 |
MAs | MA(5) : | 4.32 | MA(20) : | 3.82 |
MA(100) : | 4.56 | MA(250) : | 3.32 | |
MACD | MACD : | 0.1 | Signal : | 0 |
%K %D | K(14,3) : | 86.8 | D(3) : | 84.9 |
RSI | RSI(14): 60.9 | |||
52-week | High : | 6.71 | Low : | 1.11 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ABSI ] has closed below upper band by 18.6%. Bollinger Bands are 8.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 4.55 - 4.56 | 4.56 - 4.58 |
Low: | 4.34 - 4.36 | 4.36 - 4.37 |
Close: | 4.45 - 4.48 | 4.48 - 4.51 |
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Thu, 25 Jul 2024
12,465 Shares in Absci Co. (NASDAQ:ABSI) Bought by Avantax Advisory Services Inc. - Defense World
Tue, 23 Jul 2024
Absci (NASDAQ:ABSI) Shares Up 9.5% - MarketBeat
Wed, 10 Jul 2024
Absci to Report Business Updates and Second Quarter 2024 Financial and Operating Results on August 14, 2024 - GlobeNewswire
Sat, 29 Jun 2024
Institutional investors own a significant stake of 46% in Absci Corporation (NASDAQ:ABSI) - Yahoo Finance
Thu, 16 May 2024
Absci: 'AI' Tag Keeping Company Afloat While Searching For Right Formula (NASDAQ:ABSI) - Seeking Alpha
Tue, 14 May 2024
Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results - GlobeNewswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 113 (M) |
Held by Insiders | 8.407e+007 (%) |
Held by Institutions | 20.4 (%) |
Shares Short | 7,290 (K) |
Shares Short P.Month | 0 (K) |
EPS | -7.878e+007 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -2 % |
Return on Assets (ttm) | 616.7 % |
Return on Equity (ttm) | -20.3 % |
Qtrly Rev. Growth | 5.35e+006 % |
Gross Profit (p.s.) | -13.28 |
Sales Per Share | -20.1 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | -1.2 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -62 (M) |
PE Ratio | -0.01 |
PEG Ratio | -0.3 |
Price to Book value | 0 |
Price to Sales | -0.23 |
Price to Cash Flow | 4.64 |
Dividend | 0 |
Forward Dividend | 8.92e+006 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |